CompanyASMBNasdaqSouth San Francisco, CA

Assembly Biosciences

Assembly Biosciences develops small-molecule therapeutics for viral and liver diseases, including programs targeting herpesvirus, hepatitis delta virus, cholestatic liver diseases, and hepatitis B virus.

Stories only

SEC EDGAR ClinicalTrials.gov assemblybio.com

6-KSep 22Latest SEC filing, period to Sep 22

Aug 14Latest story

August 2026

Assembly Bio files 8-K/A to correct filing tag on Q2 2026 results release

Aug 14Quarterly updateABI-6250 Assembly Biosciences

Assembly Bio reports Q2 2026 results, expands ABI-6250 into cholestatic liver disease

Aug 13M&AABI-6250 Assembly Biosciences

Assembly Biosciences registers Phase 2 trial of ABI-6250 for chronic hepatitis D

Aug 13Trial updateABI-6250 Assembly Biosciences